LU82099A1 - Procede de preparation de derives immunoregulateurs de copolymeres de monomeres olefiniques et d'anhydrides polycarboxyliques et nouvelles compositions ainsi obtenues - Google Patents
Procede de preparation de derives immunoregulateurs de copolymeres de monomeres olefiniques et d'anhydrides polycarboxyliques et nouvelles compositions ainsi obtenues Download PDFInfo
- Publication number
- LU82099A1 LU82099A1 LU82099A LU82099A LU82099A1 LU 82099 A1 LU82099 A1 LU 82099A1 LU 82099 A LU82099 A LU 82099A LU 82099 A LU82099 A LU 82099A LU 82099 A1 LU82099 A1 LU 82099A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- semi
- imide
- tumor
- days
- approximately
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 61
- 239000000203 mixture Substances 0.000 title claims description 45
- 229920001577 copolymer Polymers 0.000 title claims description 44
- 238000002360 preparation method Methods 0.000 title claims description 36
- 150000008064 anhydrides Chemical class 0.000 title claims description 28
- 239000000178 monomer Substances 0.000 title claims description 14
- 230000004957 immunoregulator effect Effects 0.000 title claims description 13
- 230000008569 process Effects 0.000 title claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 215
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 117
- 241001465754 Metazoa Species 0.000 claims description 100
- 229910021529 ammonia Inorganic materials 0.000 claims description 48
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 45
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 29
- 125000005462 imide group Chemical group 0.000 claims description 29
- 239000008096 xylene Substances 0.000 claims description 29
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 27
- 239000005977 Ethylene Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 238000010992 reflux Methods 0.000 claims description 26
- 230000006870 function Effects 0.000 claims description 22
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical group O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 20
- 150000007942 carboxylates Chemical class 0.000 claims description 17
- 150000003839 salts Chemical group 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 168
- YYXLGGIKSIZHSF-UHFFFAOYSA-N ethene;furan-2,5-dione Chemical compound C=C.O=C1OC(=O)C=C1 YYXLGGIKSIZHSF-UHFFFAOYSA-N 0.000 description 119
- 239000000047 product Substances 0.000 description 113
- 150000003949 imides Chemical group 0.000 description 104
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 87
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 81
- 238000012360 testing method Methods 0.000 description 61
- 241000700159 Rattus Species 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- -1 polyethylene Polymers 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 48
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- 238000002513 implantation Methods 0.000 description 24
- 238000007912 intraperitoneal administration Methods 0.000 description 24
- 238000007792 addition Methods 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 18
- 150000001408 amides Chemical class 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 206010027476 Metastases Diseases 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 239000004816 latex Substances 0.000 description 15
- 229920000126 latex Polymers 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 13
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 210000002798 bone marrow cell Anatomy 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000007710 freezing Methods 0.000 description 11
- 230000008014 freezing Effects 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000004342 Benzoyl peroxide Substances 0.000 description 10
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 10
- 235000019400 benzoyl peroxide Nutrition 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 238000006358 imidation reaction Methods 0.000 description 9
- 210000004303 peritoneum Anatomy 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 229910001220 stainless steel Inorganic materials 0.000 description 9
- 239000010935 stainless steel Substances 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 238000001816 cooling Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 150000003863 ammonium salts Chemical class 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000011694 lewis rat Methods 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 150000003140 primary amides Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- 206010057249 Phagocytosis Diseases 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 6
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000003855 balanced salt solution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 101100347605 Arabidopsis thaliana VIII-A gene Proteins 0.000 description 3
- 101100347612 Arabidopsis thaliana VIII-B gene Proteins 0.000 description 3
- 208000006268 Sarcoma 180 Diseases 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012066 reaction slurry Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- OKIRBHVFJGXOIS-UHFFFAOYSA-N 1,2-di(propan-2-yl)benzene Chemical compound CC(C)C1=CC=CC=C1C(C)C OKIRBHVFJGXOIS-UHFFFAOYSA-N 0.000 description 1
- NUMXHEUHHRTBQT-AATRIKPKSA-N 2,4-dimethoxy-1-[(e)-2-nitroethenyl]benzene Chemical compound COC1=CC=C(\C=C\[N+]([O-])=O)C(OC)=C1 NUMXHEUHHRTBQT-AATRIKPKSA-N 0.000 description 1
- GVJRTUUUJYMTNQ-UHFFFAOYSA-N 2-(2,5-dioxofuran-3-yl)acetic acid Chemical compound OC(=O)CC1=CC(=O)OC1=O GVJRTUUUJYMTNQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- DNLCRLFJJIQGAR-UHFFFAOYSA-N CC1=C(C=CC=C1)C.CCCCCC.C1(=CC=CC=C1)C Chemical group CC1=C(C=CC=C1)C.CCCCCC.C1(=CC=CC=C1)C DNLCRLFJJIQGAR-UHFFFAOYSA-N 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 241000748653 Invertebrate iridescent virus 1 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 229910003251 Na K Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000143957 Vanessa atalanta Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- GMSWRMUHJLKEIL-UHFFFAOYSA-N azane;ethene Chemical group N.C=C GMSWRMUHJLKEIL-UHFFFAOYSA-N 0.000 description 1
- FKPVUQIBXAELLW-UHFFFAOYSA-N azane;oxolane-2,5-dione Chemical compound N.O=C1CCC(=O)O1 FKPVUQIBXAELLW-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 101150089047 cutA gene Proteins 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229920006225 ethylene-methyl acrylate Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000005171 halobenzenes Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ABAARDKQGYFNRQ-UHFFFAOYSA-N hexane;1,2-xylene Chemical group CCCCCC.CC1=CC=CC=C1C ABAARDKQGYFNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005382 phenolphthalein Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001749 primary amide group Chemical group 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- MPMFCABZENCRHV-UHFFFAOYSA-N tilorone Chemical compound C1=C(OCCN(CC)CC)C=C2C(=O)C3=CC(OCCN(CC)CC)=CC=C3C2=C1 MPMFCABZENCRHV-UHFFFAOYSA-N 0.000 description 1
- 229950006823 tilorone Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 238000000214 vapour pressure osmometry Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/44—Preparation of metal salts or ammonium salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/005,638 US4255537A (en) | 1979-01-22 | 1979-01-22 | Polymeric immunoregulatory agents containing half-amide/half carboxy/imide groups |
| US563879 | 1979-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU82099A1 true LU82099A1 (fr) | 1980-08-08 |
Family
ID=21716914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU82099A LU82099A1 (fr) | 1979-01-22 | 1980-01-21 | Procede de preparation de derives immunoregulateurs de copolymeres de monomeres olefiniques et d'anhydrides polycarboxyliques et nouvelles compositions ainsi obtenues |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US4255537A (enExample) |
| JP (1) | JPS55100322A (enExample) |
| AT (1) | AT368172B (enExample) |
| AU (1) | AU533497B2 (enExample) |
| BE (1) | BE881264A (enExample) |
| CA (1) | CA1140852A (enExample) |
| CH (1) | CH644874A5 (enExample) |
| DD (1) | DD148780A5 (enExample) |
| DE (1) | DE3002047A1 (enExample) |
| DK (1) | DK23780A (enExample) |
| EG (1) | EG14805A (enExample) |
| ES (1) | ES8102153A1 (enExample) |
| FI (1) | FI68060C (enExample) |
| FR (1) | FR2446843A1 (enExample) |
| GB (1) | GB2040951B (enExample) |
| GR (1) | GR68103B (enExample) |
| HU (1) | HU184229B (enExample) |
| IE (1) | IE49366B1 (enExample) |
| IL (1) | IL59172A (enExample) |
| IN (1) | IN151745B (enExample) |
| IT (1) | IT1193367B (enExample) |
| LU (1) | LU82099A1 (enExample) |
| MA (1) | MA18705A1 (enExample) |
| MW (1) | MW580A1 (enExample) |
| NL (1) | NL184900C (enExample) |
| NO (1) | NO158807C (enExample) |
| NZ (1) | NZ192649A (enExample) |
| OA (1) | OA06425A (enExample) |
| PL (1) | PL128160B1 (enExample) |
| PT (1) | PT70717A (enExample) |
| SE (1) | SE449490B (enExample) |
| ZA (1) | ZA80330B (enExample) |
| ZM (1) | ZM480A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309413A (en) * | 1979-01-22 | 1982-01-05 | Monsanto Company | Method of producing immune response by administering polymeric composition |
| US4397995A (en) * | 1980-12-29 | 1983-08-09 | Monsanto Company | Polymeric anti-tumor agent and method of preparation |
| US4517329A (en) * | 1981-06-17 | 1985-05-14 | Monsanto Company | Polymeric antitumor agent |
| US4508866A (en) * | 1981-06-17 | 1985-04-02 | Monsanto Company | Polymeric antitumor agent |
| US4510285A (en) * | 1981-06-17 | 1985-04-09 | Monsanto Company | Terpolymeric antitumor agent |
| US4501847A (en) * | 1981-07-09 | 1985-02-26 | Monsanto Company | Polymeric antitumor agent |
| US4521344A (en) * | 1982-08-30 | 1985-06-04 | Monsanto Company | Cyano-dicarboxylate |
| US4514340A (en) * | 1982-08-30 | 1985-04-30 | Monsanto Company | Cyano-polycarboxylates |
| US4442298A (en) * | 1982-08-30 | 1984-04-10 | Monsanto Company | Chemical synthesis of ethylene/maleic anhydride dimer with phenylethyl end group |
| JPS6143124A (ja) * | 1984-08-06 | 1986-03-01 | Japan Synthetic Rubber Co Ltd | 抗体の製造方法 |
| PT93772A (pt) * | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
| WO2017048719A1 (en) * | 2015-09-14 | 2017-03-23 | Saudi Arabian Oil Company | Maleic anhydride polymers and methods of treating subterranean formations |
| WO2017048707A1 (en) | 2015-09-14 | 2017-03-23 | Saudi Arabian Oil Company | Pendant epoxide polymers and methods of treating subterranean formations |
| EP3535345A1 (en) | 2016-11-04 | 2019-09-11 | Saudi Arabian Oil Company | Compositions and methods for sealing off flow channels in contact with set cement |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA664326A (en) | 1963-06-04 | E. Fields Joseph | Polymeric electrolyte-containing composition | |
| US2883287A (en) * | 1957-01-28 | 1959-04-21 | Monsanto Chemicals | Treatment of produce |
| US3157595A (en) * | 1959-09-16 | 1964-11-17 | Monsanto Co | Clarification of water with copolymers containing half-amides of olefinic anhydrides |
| GB1363512A (en) * | 1971-03-25 | 1974-08-14 | Ethylene Plastique Sa | Adhesives based on copolymer of ethylene and maleic anhydride |
-
1979
- 1979-01-22 US US06/005,638 patent/US4255537A/en not_active Expired - Lifetime
- 1979-12-19 IN IN1322/CAL/79A patent/IN151745B/en unknown
- 1979-12-27 OA OA56985A patent/OA06425A/xx unknown
-
1980
- 1980-01-18 NL NLAANVRAGE8000334,A patent/NL184900C/xx not_active IP Right Cessation
- 1980-01-18 NZ NZ192649A patent/NZ192649A/en unknown
- 1980-01-18 ES ES487819A patent/ES8102153A1/es not_active Expired
- 1980-01-21 AT AT0028480A patent/AT368172B/de not_active IP Right Cessation
- 1980-01-21 SE SE8000466A patent/SE449490B/sv not_active IP Right Cessation
- 1980-01-21 HU HU80117A patent/HU184229B/hu not_active IP Right Cessation
- 1980-01-21 FI FI800158A patent/FI68060C/fi not_active IP Right Cessation
- 1980-01-21 PT PT70717A patent/PT70717A/pt unknown
- 1980-01-21 CA CA000344034A patent/CA1140852A/en not_active Expired
- 1980-01-21 ZA ZA00800330A patent/ZA80330B/xx unknown
- 1980-01-21 GR GR60996A patent/GR68103B/el unknown
- 1980-01-21 BE BE0/199054A patent/BE881264A/fr not_active IP Right Cessation
- 1980-01-21 IE IE114/80A patent/IE49366B1/en unknown
- 1980-01-21 PL PL1980221495A patent/PL128160B1/pl unknown
- 1980-01-21 DK DK23780A patent/DK23780A/da not_active Application Discontinuation
- 1980-01-21 LU LU82099A patent/LU82099A1/fr unknown
- 1980-01-21 FR FR8001201A patent/FR2446843A1/fr active Granted
- 1980-01-21 NO NO80800137A patent/NO158807C/no unknown
- 1980-01-21 MW MW5/80A patent/MW580A1/xx unknown
- 1980-01-21 DE DE19803002047 patent/DE3002047A1/de not_active Ceased
- 1980-01-21 IT IT19343/80A patent/IT1193367B/it active
- 1980-01-21 AU AU54776/80A patent/AU533497B2/en not_active Ceased
- 1980-01-21 JP JP624880A patent/JPS55100322A/ja active Granted
- 1980-01-21 EG EG35/80A patent/EG14805A/xx active
- 1980-01-21 DD DD80218540A patent/DD148780A5/de not_active IP Right Cessation
- 1980-01-21 CH CH46180A patent/CH644874A5/de not_active IP Right Cessation
- 1980-01-21 GB GB8001923A patent/GB2040951B/en not_active Expired
- 1980-01-21 IL IL59172A patent/IL59172A/xx unknown
- 1980-01-21 MA MA18902A patent/MA18705A1/fr unknown
- 1980-01-22 ZM ZM4/80A patent/ZM480A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU82099A1 (fr) | Procede de preparation de derives immunoregulateurs de copolymeres de monomeres olefiniques et d'anhydrides polycarboxyliques et nouvelles compositions ainsi obtenues | |
| Mazo et al. | Ring opening polymerization of α-amino acids: advances in synthesis, architecture and applications of polypeptides and their hybrids | |
| TW200423947A (en) | Cyclodextrin-based polymers for therapeutics delivery | |
| KR20000024750A (ko) | 미립구를 이용한 레티노익산의 서방형 약물방출 시스템 | |
| CN1225654A (zh) | 抑制血管生成的化合物 | |
| EP0459632A1 (en) | Composition and method for controlling cholesterol | |
| JPS6133008B2 (enExample) | ||
| CN117122681A (zh) | 无载体自组装药物纳米粒子及其制备方法和应用 | |
| KR20230076761A (ko) | 저분자 콜라겐의 서방형 방출 및 체내 흡수율 증진을 위한 키토산 기반 마이크로캡슐의 제조방법 | |
| CN107405368A (zh) | 类风湿性关节炎抑制剂、类风湿性关节炎预防剂、类风湿性关节炎治疗剂及类风湿性关节炎抑制用食品 | |
| FR3022458A1 (fr) | Utilisation du mannosylglycerate et ses derives comme agent immunostimulant | |
| EP0544321B1 (en) | Use of substituted cinnamic acid polymers to treat AIDS | |
| JP2023510896A (ja) | 局所脂肪減少用気体発泡型ミセル | |
| EP0470144B1 (fr) | D-acide aspartique beta-hydroxamate pour le traitement des infections virales et des tumeurs | |
| US20100256230A1 (en) | 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof | |
| CN101060851A (zh) | 含有血液组分和或kDa的药剂及其用于预防和治疗免疫系统缺陷的用途 | |
| Asqar et al. | Complex formation of albendazole with pectin and biological activity of the product | |
| RU2185166C2 (ru) | Средство для лечения туберкулеза с низким уровнем фибротических осложнений | |
| CN114430756B (zh) | 担载短链脂肪酸酯的亲水-疏水性共聚物 | |
| EP0765662B1 (en) | Use of 5,6-o-benzylidene-l-ascorbic acid or salts thereof for the manufacture of a medicament for the treatment of hiv | |
| WO2025053156A1 (ja) | Ｎ－アシルエタノールアミン又はその同族体若しくは類似体を側鎖に有する反復単位とポリ（エチレングリコール）セグメントを含む共重合体並びに当該共重合体のナノ粒子及びその用途 | |
| CA2968483A1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
| US20100311841A1 (en) | Synthetic sphingolipid analogs | |
| JPH04210591A (ja) | 金属キレート能を賦与した化学修飾酵素 | |
| BE851113A (fr) | Acides polyvinylbenzenesulfoniques, leur procede de preparation et leur application en tant que medicaments |